(19)
(11) EP 1 765 832 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.09.2013 Bulletin 2013/39

(45) Mention of the grant of the patent:
14.08.2013 Bulletin 2013/33

(21) Application number: 05752679.0

(22) Date of filing: 13.06.2005
(51) International Patent Classification (IPC): 
C07D 498/08(2006.01)
A61P 9/06(2006.01)
 A61K 31/438(2006.01)
(86) International application number:
PCT/SE2005/000891
(87) International publication number:
WO 2005/123748 (29.12.2005 Gazette 2005/52)

(54)

NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

NEUE OXABISPIDINVERBINDUNGEN UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGEN

NOUVEAUX COMPOSES OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DES ARYTHMIES CARDIAQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30) Priority: 15.06.2004 SE 0401539

(43) Date of publication of application:
28.03.2007 Bulletin 2007/13

(73) Proprietor: Animeda AB
436 55 Hovås (SE)

(72) Inventors:
  • BJÖRE, Annika
    S-431 83 Mölndal (SE)
  • BONN, Peter
    S-431 83 Mölndal (SE)
  • GRAN, Ulrik
    S-431 83 Mölndal (SE)
  • KAJANUS, Johan
    S-431 83 Mölndal (SE)
  • OLSSON, Christina
    S-431 83 Mölndal (SE)
  • PONTEN, Fritiof
    S-431 83 Mölndal (SE)

(74) Representative: Storm, Jan Peter et al
AstraZeneca Intellectual Property Alderley Park Macclesfield
Cheshire SK10 4TG
Cheshire SK10 4TG (GB)


(56) References cited: : 
WO-A1-02/28863
 WO-A2-01/28992
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).